drugset / Trial / NCT07181161

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

NCT07181161

Phase 1/2 Recruiting 177 enrolled AstraZeneca Parexel · collab
RandomizedSequentialOpen-labelTreatment

Summary

The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.

Timeline

Start
2025-10-01
Primary completion
2029-01-18
Completion
2029-01-18

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD0516 Unknown Intravenous
Subject AZD9574 Small molecule Oral